Go Pro
OTCMKTS:BAYRY

Bayer Aktiengesellschaft Q2 2026 Earnings Report

Bayer Aktiengesellschaft logo
$14.04 -0.24 (-1.65%)
As of 04:00 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.29
Consensus EPS
$0.23
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$12.53 billion
Expected Revenue
$12.31 billion
Beat/Miss
Beat by +$216.09 million
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Deutsche Bank Reaffirms Their Buy Rating on Bayer (0P6S)
Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics. Consumer Health offers nonprescription products, including brands in pain relief, allergy care, dermatology, nutritional supplements and digestive health. Crop Science supplies seeds, crop-protection products and digital tools designed to support farmers and improve agricultural productivity.

Bayer has expanded its operations internationally through internal research and development, partnerships and acquisitions, including the acquisition of Monsanto in 2018, which strengthened its seeds and agricultural technology business. Bill Anderson has served as Bayer’s chief executive officer since June 2023 and also leads the company’s ongoing organizational transformation.

View Bayer Aktiengesellschaft Profile